Case Report

Kawasaki disease in an infant after administration of hexavalent vaccine

Meshal Z. Almeshary, MD, Saud A. Alanazi, MD, Khalid M. Almoosa, MD, Rolan K. Bassrawi, MD.

ABSTRACT

Kawasaki disease (KD) is an acute and self-limited medium-vessel vasculitis that mainly involves the coronary arteries. The pathogenesis of KD is still unknown. It appears that KD occurs as hyper-inflammatory response in a genetically predisposed individual that is possibly triggered by infectious agents or several environmental factors. We report a case of KD in an infant after administration of hexavalent vaccine.

Case Report. A 4-month-old Saudi infant with an unremarkable antenatal and perinatal history.

Clinical Findings. At the age of 4 months, he presented to the emergency department with a 9-day history of fever. He was in his usual state of good health until he developed fever 8 hours post-hexavalent vaccine (DTPa-HBV-IPV/Hib). His temperature started suddenly and was measured at home as 38.9°C axillary by his mother with no clear focus. On examination, he appeared irritable and was febrile. His temperature upon arrival was 38.6°C rectally with a heart rate of 168 beats/min and a respiratory rate of 38 breaths/min. His blood pressure was 88/50 mm Hg his oxygen saturation was 98% on room air. He developed a maculopapular rash, mainly in the upper limbs. He also had non-purulent conjunctivitis and erythematous lips but no strawberry tongue. He had neither cervical lymphadenopathy nor extremity changes.

Diagnostic assessment. A laboratory investigation upon admission showed a white blood cell (WBC) count of 17.4 ×103 cells/ul with 52% neutrophils, hemoglobin level of 11 g/dL, mean corpuscular hemoglobin level of 27, mean corpuscular volume of 80, platelets of 600/µL, C-reactive protein (CRP) level of 96 mg/L, erythrocyte segmentation rate (ESR) of 91 mm/h, and albumin level of 19.9 g/L. The normal range for laboratories: WBC: 5000-15000 cells/ul; hemoglobin: 9.5-14 g/dl; platelets: 150-450/ul; CRP: <5 mg/l, ESR: <15, and albumin: 35-45 g/l. Other laboratory workups, including urine analysis and culture, liver function tests, and renal function tests, were normal. The results of laboratory tests for infectious diseases, including nasopharyngeal aspirate for virology, multiple coronavirus disease nasal...
swabs, severe acute respiratory syndrome coronavirus 2 antibodies, and blood cultures were negative. The patient was admitted with incomplete KD.

**Therapeutic intervention.** Upon admission, he was administered 2 g/kg intravenous immunoglobulin (IVIG) along with a high dose of aspirin (80 mg/kg). The fever resolved after the first IVIG dose. The aspirin dose was decreased to the antiplatelet dose (4 mg/kg). The inflammatory markers CRP (21 mg/L) and ESR (53 mm/hour) improved in 4th day of admission with an increase in platelet count (893/µL). An echocardiogram (ECHO) was carried out on the second day of admission, showed significant dilatation of the coronary arteries as follows: left main coronary artery, 4.6 mm, Z-score of 7.3 (Figure 1A); right coronary artery, 4.2 mm in diameter, Z-score of 6.8; and left anterior descending artery, 3.8 mm, Z-score of 6.9 (Figure 1B).

**Follow-up and outcomes.** The ECHO was repeated twice 5 days apart after one week and showed no significant changes. The infant was discharged on a low dose of aspirin (4 mg/kg) daily. Follow-ups were scheduled with cardiology and rheumatology clinics after one month (Figure 2).

**Discussion.** Kawasaki disease is an acute and self-limited medium-vessel vasculitis that mainly involves the coronary arteries. The clinical manifestations of KD are highly variable, with no pathognomonic laboratory findings helpful for its diagnosis.1 In our case, the diagnosis of KD was made clinically as incomplete KD. This was further confirmed by ECHO, which showed significant dilatation of all coronary arteries. Although the pathogenesis of KD remains unknown, several theories have been suggested that may explain its cause. One such theory is an environmental trigger in patients with predisposing genetic backgrounds. However, there are no strong genetic determinants, and none can be considered real markers of disease susceptibility.2 Another theory, which is more acceptable, was proposed based on the similarity of clinical features between KD, streptococcal toxic shock syndrome, and toxic shock syndrome with evidence of superantigen-producing pathogens in all 3 diseases. These findings suggest that the immune response of KD does not result from a single agent but rather a final common inflammatory pathway in genetically susceptible individuals.3 Recently, an innate immunity disorder has been proposed as a cause of KD.4 Vaccine administration as a trigger for the development of KD remains under debate. In our case, the infant developed KD after receiving the hexavalent vaccine. Kawasaki disease has also been associated with other vaccines in clinical trials, observational studies, and case reports.5 In a matched case-control study in Colorado during a KD outbreak, 37 patients were diagnosed with KD, but there was no evidence of an association with vaccination; the odds ratio for KD within 30 days following vaccination was 1.3 (95% CI, 0.4-4.3).6 In another study, data were extracted from the Vaccine Safety Datalink to investigate the rate of KD in 1,721,186 children aged 0-6 years from 1996 to 2006. This study showed no increase in KD incidence following vaccination.7 An observational study by Hua et al8 reviewed all KD cases reported by the United

---

**Disclosure.** Authors have no conflict of interests, and the work was not supported or funded by any drug company.
States Vaccine Adverse Event Reporting System (VAERS) between 1990 and 2007. Ninety-seven cases were reported to VAERS as classic, atypical, and possible KD. Overall, the review date did not show an increased risk for all licensed vaccines. In an observer-blinded, randomized, controlled, 5-center study, 433 participants were randomly allocated to receive a single dose of Pentacel™ or Infanrix (DTaP-IPV-Hib). Only one case of KD was reported at 3 weeks after the Infanrix vaccination. A review of 15 studies published between 2000 and 2016 showed that the hexavalent vaccine was generally well-tolerated, and no vaccine-related KD cases were reported. In this case report, we discussed a case of KD that developed following the administration of hexavalent. In this case report, we discussed a very rare adverse event of post-hexavalent vaccine.

In conclusion, we cannot hypothesize that hexavalent vaccination is a trigger for KD based on a single case report, and the association observed in this child may have been coincidental.

Acknowledgment. We would like to thank Editage (www.editage.com) for English language editing.

References

1. Burns JC, Glodé MP. Kawasaki syndrome. Lancet 2004; 364: 533-544.

2. Principi N, Rigante D, Esposito S. The role of infection in Kawasaki syndrome. J Infect 2013; 67: 1-10.

3. Matsubara K, Fukaya T. The role of superantigens of group A Streptococcus and Staphylococcus aureus in Kawasaki disease. Curr Opin Infect Dis 2007; 20: 298-303.

4. Hara T, Nakashima Y, Sakai Y, Nishio H, Motomura Y, Yamasaki S. Kawasaki disease: a matter of innate immunity. Clin Exp Immunol 2016; 186: 134-143.

5. Phuong LK, Bonetto C, Buttery J, Pernus YB, Chandler R, Felicetti P, et al. Kawasaki disease and immunisation: a systematic review. Vaccine 2017; 35: 1770-1779.

6. Treadwell TA, Maddox RA, Holman RC, Belay ED, Shahriari A, Anderson MS, et al. Investigation of Kawasaki syndrome risk factors in Colorado. Pediatr Infect Dis J 2002; 21: 976-978.

7. Abrams JY, Weintraub ES, Baggs JM, McCarthy NL, Schonberger LB, Lee GM, et al. Childhood vaccines and Kawasaki disease, vaccine safety datalink, 1996-2006. Vaccine 2015; 33: 382-387.

8. Hua W, Izurieta HS, Slade B, Penina Haber, Rosemary Tierinan, et al. Table, supplemental digital content 1- vaccine adverse event reporting system (Vaers) case definitions of Kawasaki disease (Kd). Pediatr Infect Dis J 2009; 28: 943-947.

9. Halperin SA, Tapiero B, Law B, Diaz-Mitoma F, Duval B, Langley JM, et al. Interchangeability of two diphtheria and tetanus toxoids, acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b conjugate vaccines as a fourth dose in 15-20-month-old toddlers. Vaccine 2006; 24: 4017-4023.

10. Bulik NB. Hexavalent vaccine in Europe: safety data from the randomized clinical trials. Farmacia 2018; 66: 747-757.